Unexpected bleeding can be unsettling at any age, but it becomes especially puzzling when someone has gone through decades of dental work, injuries, surgeries, or childbirth without unusual bleeding and then suddenly begins bruising easily or bleeding longer than expected. In that situation, doctors may consider acquired von Willebrand syndrome (AVWS), sometimes informally called acquired von Willebrand disease.
AVWS resembles hereditary von Willebrand disease (VWD) because both involve problems with von Willebrand factor (VWF), a protein that helps platelets attach to damaged blood vessels and also protects clotting factor VIII from being cleared too quickly. The important difference is where the problem comes from. Hereditary VWD usually results from genetic changes affecting VWF, while acquired von Willebrand syndrome develops because another disease or physiologic process disrupts VWF later in life.
That distinction matters because treating AVWS often requires more than stopping the bleeding. Doctors also need to identify and, whenever possible, treat the condition that is causing VWF to disappear or malfunction in the first place.
What is acquired von Willebrand disease?
The technically preferred term is acquired von Willebrand syndrome rather than acquired von Willebrand disease. It describes an uncommon bleeding disorder in which VWF becomes quantitatively deficient, functionally abnormal, or both, despite the patient not having inherited a disease-causing VWF abnormality.
Someone with hereditary VWD may have experienced nosebleeds, easy bruising, heavy menstrual bleeding, or excessive bleeding after dental procedures since childhood or adolescence. AVWS more often appears after a period of previously normal hemostasis. A person might, for example, have had an appendectomy at age 30 without complications but develop persistent bleeding after dental work at age 68.
A negative family history is another clue. AVWS is not genetically inherited, although doctors must remember that a negative family history does not completely rule out hereditary VWD because inherited disease can be mild, underdiagnosed, or variably expressed among relatives.
Why von Willebrand factor matters
Think of VWF as part molecular glue and part bodyguard. When a blood vessel is injured, VWF helps platelets attach to exposed tissue and to one another so that the first stage of a clot can form. It also binds to factor VIII and protects that clotting protein while it circulates in the bloodstream.
VWF exists in different-sized structures called multimers. The largest multimers are particularly effective at supporting platelet adhesion. Several forms of AVWS selectively eliminate these large multimers, leaving a laboratory pattern that can look remarkably similar to type 2 hereditary VWD.
What causes acquired von Willebrand syndrome?
AVWS is less a single disease than a final destination reached by several biological routes. One patient’s immune system may remove VWF too quickly, while another patient’s abnormal blood flow may physically damage high-molecular-weight VWF multimers.
1. Monoclonal gammopathy and lymphoproliferative disorders
Some of the best-known AVWS associations involve disorders that produce abnormal populations of immune or plasma cells. Examples include monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma, certain lymphomas, chronic lymphocytic leukemia, and related lymphoproliferative conditions.
Abnormal immunoglobulins may bind to VWF, accelerating its clearance from the bloodstream or interfering with its function. In other cases, VWF can become adsorbed onto abnormal cells. Recent clinical research continues to identify lymphoproliferative diseases among the important underlying disorders associated with AVWS.
2. Myeloproliferative neoplasms
Essential thrombocythemia, polycythemia vera, and other myeloproliferative neoplasms can also produce acquired VWF abnormalities. One particularly counterintuitive situation occurs when the platelet count becomes extremely high. More platelets might sound like better clotting, but biology enjoys breaking simple rules.
Excessive platelet numbers can contribute to depletion of the large, highly active VWF multimers. A patient may therefore have both a condition associated with thrombosis and an increased tendency to bleed. This apparent contradiction is one reason hematologic evaluation is important rather than assuming that platelet count alone predicts bleeding risk.
3. Aortic stenosis and other high-shear cardiovascular conditions
Blood flowing rapidly through a severely narrowed heart valve creates significant shear stress. Under these conditions, VWF unfolds and becomes more vulnerable to proteolytic cleavage, reducing the large multimers that are especially important for platelet adhesion.
Severe aortic stenosis is the classic example. The combination of aortic stenosis, gastrointestinal bleeding from angiodysplasia, and acquired VWF abnormalities is often called Heyde syndrome. Similar VWF changes can occur with left ventricular assist devices (LVADs), some congenital cardiac lesions, hypertrophic cardiomyopathy, extracorporeal mechanical circulatory support, and other high-shear states.
4. Autoimmune disease
Autoimmune disorders such as systemic lupus erythematosus have occasionally been associated with AVWS. Autoantibodies may interfere directly with VWF or cause it to disappear from the circulation faster than normal.
Testing for an inhibitor or VWF-binding antibody may sometimes help, but the absence of detectable antibodies does not exclude AVWS. The immune mechanism can be complicated, and clinically significant accelerated clearance may exist even when standard antibody tests are negative.
5. Hypothyroidism
Severe hypothyroidism is a less common but established association. In this situation, reduced production rather than destruction of VWF may contribute to the abnormality. VWF measurements can improve when the thyroid disorder is successfully treated, making this one of the clearer examples of why identifying the underlying cause matters.
6. Cancer and other uncommon causes
AVWS has been reported with selected solid tumors and other uncommon medical conditions. Certain medications have also been linked to acquired VWF abnormalities in case reports and reviews. However, these associations are much less common than hematologic or cardiovascular causes, and an abnormal VWF result should not automatically be blamed on a medication without a careful assessment.
Symptoms of acquired von Willebrand syndrome
AVWS generally produces the type of bleeding associated with impaired primary hemostasis. Common manifestations can include:
- New or unusually easy bruising
- Frequent or prolonged nosebleeds
- Bleeding from the gums
- Persistent bleeding after dental work
- Longer-than-expected bleeding after surgery
- Gastrointestinal bleeding
- Heavy menstrual bleeding in people who menstruate
- Iron-deficiency anemia caused by chronic blood loss
More severe bleeding can occur, although the pattern varies substantially according to the VWF defect and underlying condition. Anyone experiencing uncontrolled bleeding, vomiting blood, black or bloody stools, significant blood loss, neurologic symptoms after an injury, or symptoms such as fainting and severe weakness requires prompt medical evaluation.
Acquired vs. hereditary von Willebrand disease
| Feature | Acquired von Willebrand syndrome | Hereditary VWD |
|---|---|---|
| Underlying cause | Another medical disorder or physiologic process | Usually pathogenic or disease-associated genetic variation affecting VWF |
| Inheritance | Not inherited | Can be autosomal dominant or autosomal recessive depending on subtype |
| Typical onset | Often later in life | Present from birth, although symptoms may not appear until later |
| Earlier bleeding history | Often absent | May include childhood nosebleeds, bruising or procedure-related bleeding |
| Family history | Usually negative | May be positive, but not always obvious |
| Associated disease | Often present | Not required |
| Laboratory appearance | Can resemble type 1 or type 2 VWD | Depends on hereditary subtype |
| Genetic testing | No inherited VWF cause expected | May identify a VWF variant in selected cases |
| Long-term strategy | Treat bleeding plus underlying cause when possible | Manage the inherited bleeding disorder throughout life |
Hereditary VWD is usually divided into types 1, 2, and 3. Type 1 involves a partial quantitative deficiency. Type 2 includes several qualitative abnormalities2A, 2B, 2M, and 2Nwhile type 3 typically involves extremely low or absent VWF and is generally the most severe inherited form.
How doctors diagnose acquired von Willebrand syndrome
Diagnosis is rarely based on one magic blood test. VWF levels naturally fluctuate with stress, inflammation, pregnancy, exercise, age, medications, and other physiologic variables. For that reason, testing may need to be repeated or interpreted by a hematologist familiar with bleeding disorders.
Clinical history comes first
Doctors often ask whether abnormal bleeding is new, whether previous operations or dental procedures were uneventful, and whether relatives have similar symptoms. Late-onset bleeding with previously normal surgical hemostasis and no family history raises suspicion for AVWS.
Laboratory testing
The evaluation may include:
- Complete blood count and platelet count
- Prothrombin time and activated partial thromboplastin time
- VWF antigen concentration
- VWF activity testing
- Factor VIII activity
- VWF activity-to-antigen relationships
- VWF multimer analysis in selected cases
- Additional specialized platelet or VWF assays
The pattern can reveal whether there is mainly too little VWF or whether the protein is present but performs poorly. Multimer testing can be particularly useful when clinicians suspect selective loss of high-molecular-weight multimers.
If AVWS appears likely, the investigation then expands toward the possible underlying disorder. Depending on the clinical situation, this could involve evaluation for monoclonal proteins, hematologic malignancy, abnormal blood cell counts, thyroid disease, autoimmune illness, or structural heart disease.
How acquired von Willebrand syndrome is treated
There is no universal AVWS treatment plan because the mechanism matters. Management generally has three goals: control active bleeding, prevent bleeding during high-risk situations, and treat the underlying cause whenever possible.
Treating the underlying disorder
This is often the most important long-term strategy. Correcting severe aortic stenosis can improve shear-related VWF abnormalities. Treating hypothyroidism may normalize VWF production. Successful treatment of certain lymphomas, myeloma, or other hematologic disorders can sometimes result in improvement or remission of AVWS.
The relationship is not perfectly predictable, however. Treating the associated disease does not guarantee immediate normalization of bleeding, so hematologic monitoring may still be required.
Desmopressin
Desmopressin, or DDAVP, stimulates endothelial cells to release stored VWF. It works very well for some forms of hereditary VWD but can produce a shorter or less reliable response in AVWS because newly released VWF may again be rapidly removed or destroyed.
When clinically appropriate, hematologists may evaluate the patient’s laboratory response before relying on desmopressin for a procedure. Fluid management and patient-specific contraindications also matter, which is why DDAVP should not be treated as a do-it-yourself bleeding remedy.
VWF-containing replacement therapy
VWF concentrates may be used to control significant bleeding or provide hemostatic coverage for surgery. The duration of benefit can be shorter in AVWS than hereditary disease because the same mechanism responsible for removing the patient’s natural VWF may also accelerate removal of infused VWF.
Recombinant VWF and plasma-derived VWF products are available for VWD management in the United States, although product selection and use in AVWS must be individualized by specialists rather than assumed from hereditary VWD protocols.
Intravenous immunoglobulin
Intravenous immunoglobulin (IVIG) can be especially useful in selected immune-mediated forms of AVWS, notably some patients with IgG monoclonal gammopathy. The response is not immediate and is not equally effective across all paraprotein types, so treatment is chosen according to the underlying mechanism.
Antifibrinolytic medicines
Medicines such as tranexamic acid can help stabilize clots and may be useful for certain mucosal or procedure-related bleeding situations. They do not correct the underlying VWF abnormality but can provide valuable additional hemostatic support.
Practical experiences: what the AVWS journey can look like
The following scenarios are illustrative examples based on patterns described in clinical literature rather than individual patient testimonials. They show why acquired von Willebrand syndrome frequently requires medical detective work.
Experience 1: “I never used to bleed like this.”
Consider an older adult who has had several operations over the years without excessive bleeding. Recently, however, the person develops recurrent gastrointestinal blood loss, iron-deficiency anemia, and bruises that seem disproportionately large. A routine coagulation panel does not immediately reveal the answer.
The important clue is not simply that bleeding exists. It is that the bleeding pattern changed. Previous normal surgical history makes a severe lifelong inherited disorder less likely. If the same patient has significant aortic stenosis, clinicians may investigate shear-related loss of high-molecular-weight VWF multimers and the possibility of Heyde syndrome.
This kind of case demonstrates why telling a clinician, “I’ve never had this problem before,” is medically useful information rather than casual conversation.
Experience 2: abnormal bleeding leads to another diagnosis
Another common diagnostic pattern begins with persistent nosebleeds, unexplained bruising, or bleeding after dental extraction in an adult with no family history of bleeding. VWF activity is unexpectedly low relative to antigen, prompting additional hematology testing.
Further evaluation may uncover a monoclonal protein and eventually MGUS or another plasma-cell or lymphoid disorder. In this situation, AVWS is not merely a label for the bleeding. It can function as a clue pointing toward an underlying condition that had not previously produced obvious symptoms.
This is why doctors typically resist treating an acquired VWF abnormality in isolation. Stopping today’s nosebleed solves today’s problem; understanding why VWF disappeared may solve a much larger one.
Experience 3: a high platelet count but more bleeding
A person with essential thrombocythemia might logically assume that having too many platelets should make bleeding impossible. Then bruising or mucosal bleeding appears, creating considerable confusion.
In certain myeloproliferative disorders, extremely elevated platelet counts can be accompanied by loss of the largest VWF multimers and reduced VWF function. The laboratory picture can therefore reveal acquired von Willebrand syndrome even though the platelet count is high.
The practical lesson is that clotting is a system, not a scoreboard where more platelets automatically equal more clotting. VWF quality, platelet function, blood flow, coagulation factors, medications, and the underlying disease all interact.
Experience 4: preparing for surgery changes everything
Sometimes AVWS is discovered before an operation rather than during spontaneous bleeding. Imagine a patient with a newly recognized monoclonal gammopathy who needs surgery. A history review reveals recent easy bruising, and specialized tests demonstrate impaired VWF activity.
Instead of simply proceeding and hoping for the besta strategy rarely celebrated in hematologythe care team can plan ahead. Depending on the mechanism and procedure, hematologists may evaluate responses to desmopressin, VWF replacement, IVIG, antifibrinolytic therapy, or combinations of treatments. Laboratory measurements before and after treatment can show whether the effect lasts long enough to provide surgical hemostasis.
Experience 5: the diagnosis evolves with the underlying disease
AVWS is unusual because the bleeding disorder itself can improve when its trigger improves. Someone whose VWF abnormality results from hypothyroidism may experience normalization after appropriate thyroid treatment. A patient with shear-related AVWS may improve after correction of a severe cardiac lesion. Treatment of an associated hematologic malignancy may also reduce the VWF problem in selected patients.
That creates an important difference from hereditary VWD. A person born with a disease-causing VWF variant generally manages that inherited tendency throughout life. AVWS may instead behave like a downstream complication: remove or control the upstream problem and the bleeding abnormality may lessen.
Still, patients should not assume that improvement in the underlying condition automatically means bleeding risk has disappeared. Follow-up laboratory testing and specialist guidance are usually necessary before surgery, dental work, or changes in bleeding-related medication.
When should you see a hematologist?
Evaluation is especially important when abnormal bleeding begins unexpectedly in adulthood, becomes substantially worse than it used to be, occurs alongside a blood disorder or heart disease, or results in anemia or repeated medical treatment.
A hematologist can distinguish AVWS from hereditary VWD, platelet disorders, medication-related bleeding, liver disease, factor deficiencies, and other causes. Because management can vary dramatically depending on the mechanism, getting the diagnosis right is more useful than simply attaching the word “bleeding disorder” to the chart.
Conclusion
Acquired von Willebrand syndrome can closely imitate hereditary von Willebrand disease, but its origin is fundamentally different. Hereditary VWD results from an inherited predisposition affecting VWF, whereas AVWS develops because another condition changes VWF production, function, multimer structure, or clearance.
Monoclonal gammopathies, lymphoproliferative disorders, myeloproliferative neoplasms, autoimmune diseases, hypothyroidism, and high-shear cardiovascular conditions are among the better-recognized associations. The strongest diagnostic clues are often late-onset bleeding, previously normal hemostatic challenges, a negative family history, characteristic VWF laboratory abnormalities, and the presence of an associated medical condition.
Treatment therefore works on two levels: control the immediate bleeding risk and investigate what is disrupting VWF. With specialist evaluation, AVWS can often be managed effectively, and in some cases correcting the underlying problem can substantially improve the bleeding disorder itself.
Medical note: This article is educational and should not be used to diagnose or treat abnormal bleeding. Uncontrolled bleeding, major gastrointestinal bleeding, significant bleeding after trauma, or symptoms suggesting substantial blood loss require urgent medical care.
Research note: The medical information above was synthesized from U.S. and U.S.-hosted authoritative resources including the National Heart, Lung, and Blood Institute, CDC, American Society of Hematology, Mayo Clinic, Cleveland Clinic, MedlinePlus, NCBI/GeneReviews, NCBI StatPearls, PubMed-indexed hematology literature, Blood, Hematology & Oncology, FDA, and DailyMed, including recent 2026 research on acquired von Willebrand syndrome.